Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Sadoff, Jerald; Gray, Glenda; Vandebosch, An; Cárdenas, Vicky; Shukarev, Georgi; Grinsztejn, Beatriz; Goepfert, Paul; Truyers, Carla; Van Dromme, Ilse; Spiessens, Bart; Vingerhoets, Johan; Custers, Jerome; C. Scheper, Gert; L. Robb, Merlin; J. Treanor, John; Ryser, Martin; H. Barouch, Dan; Swann, Edith; Marovich, Mary; M. Neuzil, Kathleen; Corey, Lawrence; J. Stoddard, Jeffrey; Hardt, Karin; Ruiz‐Guiñazú, Javier; Le Gars, Mathieu; Schuitemaker, Hanneke; Van Hoof, Johan; Struyf, Frank; Douoguih, Macaya

doi:10.1056/nejmoa2117608

Public

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S

Published in New England Journal of Medicine • Feb 9, 2022

Authors:

Jerald Sadoff

Glenda Gray

An Vandebosch

Abstract

BACKGROUND: The Ad26.COV2.S vaccine was highly effective against severe-critical coronavirus disease 2019 (Covid-19), hospitalization, and death in the primary phase 3 efficacy analysis. METHODS: viral particles) or placebo. The primary end points were vaccine efficacy against moderate to severe-cri...

Subject

Medicine

Clinical efficacy

Coronavirus disease 2019 (COVID-19)

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!